Von Willebrand Diseases
26
11
12
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
3.8%
1 terminated out of 26 trials
91.7%
+5.2% vs benchmark
15%
4 trials in Phase 3/4
45%
5 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (26)
ATHNdataset Registry
Development of a Device for Evaluating Primary Hemostasis Under Whole Blood Flow Conditions
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Von Willebrand Factor in Pregnancy (VIP) Study
Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients
Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial
The Lived Experience of People With Von Willebrand Disease
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
Real-life Data of Constitutional Von Willebrand Disease in Western France
ATHN 9: Severe VWD Natural History Study
Cardiovascular and Venous Thromboembolism Disease in Patients with Von Willebrand Disease in the French West
A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWD
Minimize Menorrhagia in Women With Von Willebrand Disease
Impact of Von Willebrand Factor and Its Multimers on Angiogenesis
Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD
Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases
World Bleeding Disorders Registry
BT200 in Hereditary Bleeding Disorders